Suppr超能文献

头高位倾斜试验和三磷酸腺苷试验在评估血管迷走性晕厥机制中的作用:初步结果及潜在治疗意义

Contribution of head-up tilt testing and ATP testing in assessing the mechanisms of vasovagal syndrome: preliminary results and potential therapeutic implications.

作者信息

Flammang D, Erickson M, McCarville S, Church T, Hamani D, Donal E

机构信息

Angoulême General Hospital, Saint Michel, France.

出版信息

Circulation. 1999 May 11;99(18):2427-33. doi: 10.1161/01.cir.99.18.2427.

Abstract

BACKGROUND

In patients with vasovagal syndrome, head-up tilt testing may reproduce symptoms generally associated with vasodepression. Recent research suggests ATP testing identifies patients with abnormal vagal cardiac inhibition. This preliminary study examined the joint contribution of both tests in identifying underlying mechanisms in the general population with vasovagal syndrome.

METHODS AND RESULTS

Both tests were performed in random order during 1 session and outside of predominant sympathetic periods in 72 patients hospitalized for syncope (n=56) or presyncope (n=16) for whom no cardiac or extracardiac cause was found. For passive and isoproterenol-provocative tilt testing by standard protocol, reproduction of symptoms defined a positive test. The ATP test consisted of injecting ATP 20 mg IV at bedside, continuously monitoring ECG and blood pressure; a vagal cardiac pause >10 seconds defined a positive test. For most patients (64%), >/=1 test was positive. Of the 41 patients (57%) with a positive tilt test (either passive or provoked by isoproterenol), 32% had cardiac disease; none had significant bradycardia (<50 bpm). Of the 8 patients (11%) with a positive ATP test, 62% had cardiac disease; the probability of a positive result increased with age (P=0.015). Both tests were positive in 3 patients and negative in 26 patients; the tilt and ATP test results were uncorrelated (P=0.28).

CONCLUSIONS

Results suggest tilt and ATP tests individually and jointly determine the mechanism of vasovagal symptoms in most patients and that vagal cardiac inhibition increases with age.

摘要

背景

在血管迷走性晕厥综合征患者中,头高位倾斜试验可能会重现通常与血管抑制相关的症状。最近的研究表明,三磷酸腺苷(ATP)试验可识别出迷走神经心脏抑制异常的患者。这项初步研究探讨了这两种试验在确定血管迷走性晕厥综合征普通人群潜在机制中的联合作用。

方法与结果

在72例因晕厥(n = 56)或晕厥前症状(n = 16)住院且未发现心脏或心外病因的患者中,在同一时段以随机顺序进行这两种试验,且在交感神经活动不占主导的时段进行。对于标准方案的被动和异丙肾上腺素激发倾斜试验,症状重现定义为试验阳性。ATP试验包括在床边静脉注射20mg ATP,持续监测心电图和血压;迷走神经心脏停搏>10秒定义为试验阳性。大多数患者(64%)至少有一项试验呈阳性。在41例倾斜试验阳性(被动或异丙肾上腺素激发)的患者中(57%),32%患有心脏病;无一例有显著心动过缓(<50次/分钟)。在8例ATP试验阳性的患者中(11%),62%患有心脏病;阳性结果的概率随年龄增加(P = 0.015)。3例患者两种试验均为阳性,26例患者两种试验均为阴性;倾斜试验和ATP试验结果不相关(P = 0.28)。

结论

结果表明,倾斜试验和ATP试验单独及联合使用可确定大多数患者血管迷走性症状的机制,且迷走神经心脏抑制随年龄增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验